⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLXN News
Silexion Therapeutics Corp Ordinary Shares
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
globenewswire.com
SLXN
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
globenewswire.com
SLXN
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
globenewswire.com
SLXN
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
SLXN
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
globenewswire.com
SLXN
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
globenewswire.com
SLXN